ha receptor

(S)-(-)-HA 966 is a NMDA receptor antagonist which exhibits potent anticonvulsant effects and has shown efficacy in experimental models of neurological diseases.

Alimemazine (Trimeprazine) is generally used as an antipruritic agent and also a hemagglutinin (HA)-receptor antagonist. Alimemazine also acts as a partial agonist against the histamine H1 receptor (H1R) and other GPCRs.

HA-117 is a dopamine receptor agonist.

HA-966 HCl is an NMDA receptor complex glycine site antagonist.

HA-966 trihydrate is an NMDA receptor complex glycine site antagonist.

hA3AR agonist 1 is a potent human A3 adenosine receptor (hA3AR) agonist with a Ki of 2.40 nM.

A1AR antagonist 2 (compound 18h) is a potent antagonist of the A1 adenosine receptor (AR) with Ki values of 1.49, 10.2, and 50.1 nM for hA1, hA2A, and hA2B, respectively [1].

AKP-11 is a sphingosine-1-phosphate receptor 1 (S1P1) agonist with an EC50 of 0.047 μM for [35S]GTPγS binding to CHO-K1 cell membranes expressing human S1P1. It reduces S1P1 surface expression and enhances Akt and ERK phosphorylation in CHO cells with S1P1-HA at a 100 nM concentration. At doses of 1.3 and 3 mg kg, AKP-11 lowers IFN-γ and IL-17 protein levels in the spinal cord and mitigates disease severity in a rat experimental autoimmune encephalomyelitis (EAE) model. Additionally, it decreases peripheral total lymphocyte and specific T cell subsets (CD4+, CD8+, and CD26L+ T cells) counts in both EAE rats and healthy controls at a 1.3 mg kg dosage.

HA-118 is a dopamine receptor agonist.